Mytos

Mytos is developing robotic systems designed for the automated manufacturing of human cells. Their platform enables operators to input stem cells, which are then transformed into specialized cell types, such as neurons and heart cells, over a period of several weeks. This innovative approach addresses the critical need for scalable cell production in regenerative medicine.

Recent medical breakthroughs have demonstrated the potential of stem cell-derived cells in treating conditions like Parkinson's disease, vision loss, and Type 1 diabetes. However, current global production capacity is insufficient to meet the demand for these therapies, hindering their accessibility to millions of patients. The traditional manual methods of producing regenerative medicines are both costly and limit scalability.

Mytos aims to overcome these limitations by fully automating the cell production process, enabling significant scaling. They have secured their first manufacturing agreement to produce neurons for Parkinson's disease treatment and are actively engaged in discussions with other leading companies in the field.